N-methylanatoxinol isomers: derivatives of the agonist (+)-anatoxin-a block the nicotinic acetylcholine receptor ion channel. 1989

K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201.

Using biochemical and patch-clamp techniques, we investigated the pharmacology of S- and R-epimers of N-methylanatoxinol, which are analogs of the semi-rigid, stereoselective, nicotinic agonist (+)-anatoxin-a. In contrast to (+)-anatoxin-a, both isomers had poor ability to inhibit the binding of 125I-alpha-bungarotoxin or to open acetylcholine channels, and they were unable to elicit contracture of frog rectus abdominis muscles. However, both isomers were able to demonstrate significant concentration-dependent blockade of the nicotinic acetylcholine receptor ion channel. The R-isomer was approximately 4-fold more potent in causing inhibition of [3H]H12HTX binding than was the S-isomer, in the absence of carbamylcholine. In the presence of carbamylcholine, the affinity of the R-isomer of N-methylanatoxinol for the ion channel sites was further enhanced, so that its affinity became much greater than that of the S-isomer. Refinement of voltage- and concentration-dependent terms for the ion channel blocking and unblocking rates yielded functions that were able to predict the channel open times and short closed times well. The S-isomer bound and dissociated from the ion channel site of the nicotinic acetylcholine receptor more rapidly and with greater voltage sensitivity than the R-isomer. The present characterization of the antagonistic properties of these new analogs of (+)-anatoxin-a introduces a new aspect to the molecular pharmacology of (+)-anatoxin-a analogs; the semi-rigid compounds could be useful in describing the allosteric binding sites of the acetylcholine receptor, as well as in delimiting the agonist binding site.

UI MeSH Term Description Entries
D007473 Ion Channels Gated, ion-selective glycoproteins that traverse membranes. The stimulus for ION CHANNEL GATING can be due to a variety of stimuli such as LIGANDS, a TRANSMEMBRANE POTENTIAL DIFFERENCE, mechanical deformation or through INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS. Membrane Channels,Ion Channel,Ionic Channel,Ionic Channels,Membrane Channel,Channel, Ion,Channel, Ionic,Channel, Membrane,Channels, Ion,Channels, Ionic,Channels, Membrane
D008387 Marine Toxins Toxic or poisonous substances elaborated by marine flora or fauna. They include also specific, characterized poisons or toxins for which there is no more specific heading, like those from poisonous FISHES. Marine Biotoxins,Phycotoxins
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D011894 Rana pipiens A highly variable species of the family Ranidae in Canada, the United States and Central America. It is the most widely used Anuran in biomedical research. Frog, Leopard,Leopard Frog,Lithobates pipiens,Frogs, Leopard,Leopard Frogs
D011978 Receptors, Nicotinic One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors. Nicotinic Acetylcholine Receptors,Nicotinic Receptors,Nicotinic Acetylcholine Receptor,Nicotinic Receptor,Acetylcholine Receptor, Nicotinic,Acetylcholine Receptors, Nicotinic,Receptor, Nicotinic,Receptor, Nicotinic Acetylcholine,Receptors, Nicotinic Acetylcholine
D001952 Bridged-Ring Compounds Cyclic hydrocarbons that contain multiple rings which share one or more bridgehead connections. Bridged Compounds,Bridged Ring Compounds
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000087522 Cyanobacteria Toxins Toxic secondary metabolites produced CYANOBACTERIA. Cyanobacterial Neurotoxin,Cyanobacterial Neurotoxins,Cyanobacterial Toxins,Cyanotoxins,Neurotoxin, Cyanobacterial
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001427 Bacterial Toxins Toxic substances formed in or elaborated by bacteria; they are usually proteins with high molecular weight and antigenicity; some are used as antibiotics and some to skin test for the presence of or susceptibility to certain diseases. Bacterial Toxin,Toxins, Bacterial,Toxin, Bacterial

Related Publications

K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
January 1991, NIDA research monograph,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
April 1989, Sheng li ke xue jin zhan [Progress in physiology],
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
July 1986, European journal of biochemistry,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
May 1995, European journal of pharmacology,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
June 1993, Journal of neurochemistry,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
August 1987, FEBS letters,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
November 1980, Molecular pharmacology,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
March 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
April 1982, Proceedings of the National Academy of Sciences of the United States of America,
K L Swanson, and Y Aracava, and F J Sardina, and H Rapoport, and R S Aronstam, and E X Albuquerque
January 2002, Bioorganicheskaia khimiia,
Copied contents to your clipboard!